市場調查報告書
商品編碼
1152297
組織診斷的全球市場:各產品類型、技術、癌症類型、終端用戶 - 預測(~2029年)Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments ), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End user - Global Forecast to 2029 |
全球組織診斷的市場規模,至2029年達到85億2,000萬美元,2022年~2029年預計以7.4%的年複合成長率成長。市場成長,起因於全球癌症罹患率的上升,生物標記的可用性與生物標記相關的研究,癌症篩檢的推薦,癌症治療藥的臨床試驗增加,組織為基礎的伴隨式診斷的可用性。
本報告提供全球組織診斷市場相關調查分析,市場考察,市場區隔分析,地區分析,競爭情形等資訊。
Tissue Diagnostics Market by Product Type (Antibodies, Kits, Reagents, Instruments [Slide Stainer, Scanner]), Technology (Digital Pathology, IHC, ISH, H&E Staining), Cancer Type (Breast, NSCLC, Colorectal, Prostate), and End user-Global Forecast to 2029
The tissue diagnostics market is projected to reach $8.52 billion by 2029, at a CAGR of 7.4% from 2022 to 2029.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the tissue diagnostics market is attributed to the rising prevalence of cancer globally, the availability of biomarkers and research on biomarkers, recommendations for cancer screening, the growing number of clinical trials for oncology drugs, and the availability of tissue-based companion diagnostics. Additionally, emerging economies, growing developments in personalized medicines, and the shift towards automation are likely to offer significant growth opportunities for the tissue diagnostics market.
Based on product type, in 2022, the consumables segment is expected to account for the largest share of the market. The key factors attributing to the large market share of this segment are the repetitive need for consumables and technological advances in developing novel consumables. For instance, in May 2022, Qiagen N.V. (Netherlands) launched its therascreen EGFR Plus RGQ PCR Kit, a new in-vitro diagnostic test for sensitive EGFR mutation analysis. It detects all the currently known activating and resistance EGFR mutations.
Based on technology, in 2022, the immunohistochemistry segment is expected to account for the largest share of the market. Immunohistochemistry provides variations between different types of tumors over conventional enzyme staining techniques; thus, the adoption of IHC for conducting immunodiagnostics tests and point-of-care diagnostic tests for tissue diagnostics is high. This contributes to the large market share of this segment.
Based on application, the tissue diagnostics market is segmented into breast cancer, lung cancer, colorectal and gastrointestinal cancer, prostate cancer, lymphatic cancer, and others. In 2022, the breast cancer segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the high prevalence of breast cancer and the presence of several research and screening programs. For instance, in October 2021, The Breast Cancer Research Foundation (BCRF) announced USD 47.5 million in funding to support breast cancer research during 2021-22.
Based on end user, in 2022, the hospitals and reference laboratories segment is expected to account for the largest share of the market. The rising prevalence of cancer globally and the subsequent high inflow of patients to hospitals and reference laboratories support the large market share of this segment.
An in-depth analysis of the geographical scenario of the tissue diagnostics market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to account for the largest share of the tissue diagnostics market. The high incidence rate of cancer, access to a number of public programs to minimize cancer incidence, technological advancements, and the adoption of personalized medicine attribute to the large market share of this regional market.
Some of the key players operating in the global tissue diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott Laboratories (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Sigma-Aldrich Co. LLC) (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Abcam plc (U.K.), Becton, Dickinson, and Company (U.S.), QIAGEN N.V. (Netherlands), Cell Signaling Technology, Inc. (U.S.), Bio-Genex Laboratories, Inc. (U.S.), Bio SB, INC (U.S.), 3DHISTECH Ltd. (Hungary), and HOLOGIC, INC. (U.S.).
Global Tissue Diagnostics Market, by Product Type
Consumables
Instruments
Note: Other instruments include microarrays and embedding systems.
Global Tissue Diagnostics Market, by Technology
Immunohistochemistry (IHC)
In-situ Hybridization (ISH)
Digital Pathology
H&E Slide Staining
Other Technologies
Note: Other technologies include molecular, immunofluorescence, and special staining
Global Tissue Diagnostics Market, by Application
Breast Cancer
Lung Cancer
Colorectal and Gastrointestinal Cancer
Prostate Cancer
Lymphatic Cancer
Other Applications
Note: Other applications include cervical cancer, melanoma, lip, oral cavity cancer
Global Tissue Diagnostics Market, by End User
Hospitals and Reference Laboratories
Research Institutes
Pharmaceutical Companies
Contract Research Organization
Global Tissue Diagnostics Market, by Geography